Hortensia Fussy

Kendamil Launches First European Infant Goat Formula to Challenge "Medicalized" Formula Category

Retrieved on: 
Monday, August 21, 2023
UNESCO, Heart, Selenium, University, Pediatrics, Palm oil, Target Corporation, Hortensia Fussy, Digestion, Parent, Lake District, Michelin, A2, Nutrient, Constipation, Immunity, Food quality, Absorption, Monde Selection, Oligosaccharide, Nutritional science, Milk, Health maintenance organization, Cognitive development, Nature, Child, Love, Serra Grande Gold Mine, World Heritage Site, Entrepreneurship, Infant, Milk allergy, Lactose, Sucrose, Royal family, Breast milk, Dairy, Dietary supplement, Toy, Tourism, Target

KENDAL, England, Aug. 21, 2023 /PRNewswire/ -- Kendamil, the family-run infant nutrition company and fastest growing formula brand in the United States is proud to introduce its 'naturally gentle' Goat Milk Infant and Toddler Formula range to the U.S., launching in Target stores nationwide and online at Target.com.

Key Points: 
  • Exclusively launching at Target, Kendamil Goat utilizes the unique and scientifically validated properties of goat milk to provide parents a new, naturally gentle option for their babies.
  • Kendamil will disrupt an over-medicalized U.S. formula market with a novel, nutritionally complete alternative catering to infants from birth through to three years-of-age, available nationwide.
  • This means Goat formula may offer a gentler, more natural alternative for common infant feeding issues including gas, fussiness, reflux and constipation.
  • For years, U.S. parents have sought European-made goat infant formula for their little ones – and as the most searched-for goat formula brand in the U.S., Kendamil is proud to fulfill that need for families nationwide.

FDA Authorizes Marketing of Kabrita's Goat Milk-Based Infant Formula in the US

Retrieved on: 
Tuesday, July 11, 2023
US Food Sovereignty Alliance, Hortensia Fussy, Parent, Colic, Infant formula, Science, Milk, Pesticide, Kabri, Israel, Randomized controlled trial, Growth, Infant, Lactose, FDA, Food, Safety, Farm, Breast milk, Dairy, Birth control

BOSTON, July 11, 2023 /PRNewswire/ -- Kabrita USA, a division of Ausnutria, a company with over 75 years of infant formula expertise and experience worldwide, announced today that its Kabrita Goat Milk-Based Infant Formula (0-12 months) meets all the US Food and Drug Administration's (FDA) nutrition and safety requirements and is authorized to market in the US. Kabrita Goat Milk-Based Infant Formula is expected to be available in the US later this year.

Key Points: 
  • Kabrita's Goat Milk-Based Infant Formula is the first European infant formula to meet the FDA's nutrition and safety requirements and will increase availability of infant formula across the country.
  • Kabrita Goat Milk-Based Infant Formula is expected to be available in the US later this year.
  • The FDA authorization of Kabrita Goat Milk-Based Infant Formula expands the Kabrita brand in the United States; Kabrita Goat Milk-Based Toddler Formula has been available in the US market since 2014.
  • To learn more about the science behind Kabrita Goat Milk-Based Infant Formula, please visit GetToKnowGoat.com .

New Study on the Prevention of Postpartum Depression: Intervention With SNOOⓇ May Reduce PPD Rates By 20-50%

Retrieved on: 
Tuesday, May 24, 2022
Insomnia, Risk, History, Mother, Hospital, Cooking, Incidence, Multimedia, Woman, University, PPD, Parent, Hortensia Fussy, Depressive, Associate, Infant, COVID-19, Sleep deprivation, Depression, University of Colorado Colorado Springs, Harvey Karp, Sleep, Partnership, Child, Anxiety, UCCS, Comparative effectiveness research, Mental health, Brigham and Women's Hospital, COVID, LOS, NICU, Uranium, Birth control, Pharmaceutical industry, Medicine, Toy, Research, Block

LOS ANGELES, May 24, 2022 /PRNewswire/ -- Researchers at The University of Colorado partnered with Happiest Baby, makers of SNOO, to study the link between sleep and rates of postpartum depression (PPD). Findings suggest that the smart bassinet's ability to soothe infant crying and fussiness holds substantial potential to support new parents and significantly reduce rates of postpartum depression.

Key Points: 
  • Findings suggest that the smart bassinet's ability to soothe infant crying and fussiness holds substantial potential to support new parents and significantly reduce rates of postpartum depression.
  • While 18.2% using SNOO met the clinical criteria for insomnia, this was lower than the expected incidence of approximately 46% .
  • Yet, in this study, mothers with prior depressionwho used SNOO had less PPD than those at low risk.
  • SNOO is not cleared or approved for the prevention or treatment of anxiety, insomnia, depression, or postpartum depression (PPD).